hotspot -WSS

hotspot

author：fashion 2025-09-04 05:52:34 - browse：3

A yellow number 3 with an eye is surrounded by smaller, black number 3s on a pink background — 3 to watch coverage from STAT — Christine Kao/STAT

Health tech hopefuls might once have been used to a wealth of job options, especially in the pandemic’s early stages when investors pumped record-breaking dollar amounts into an unprecedented number of ventures.

That glut of opportunities meant workers could bargain harder for better job offers, demanding perks and flexibilities like permanent remote work or expensive fertility benefits. But belt-tightening and market consolidation across health tech companies have tipped the scales back in favor of employers, who are continuing to hire — for a seemingly dwindling number of positions.

It might feel like a downturn, although it’s possible that the industry is simply easing back into its pre-pandemic normal, before the massive infusion of venture dollars and the hype surrounding virtual care, said Brookings Institution research fellow Niam Yaraghi, who studies health care employment.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： New CMS data security rules will hurt Medicare, Medicaid research

WSS

After sickle

Obamacare plans could cover weight loss drugs

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Surprise medical billing ban raises prices elsewhere

Reporting on presidential health from Reagan to Trump and Biden

Radiology is caught between AI's potential and concern for patients

hotspot

hotspot

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Pfizer plans to depart BIO

ChatGPT in medicine: STAT answers readers' burning questions

Elevance, SCAN deals highlight health insurer acquisition scrutiny

The cancer drug shortage isn’t new — and neither are the solutions

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Sports medicine is finally prioritizing gender equality

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

In age of alternative facts, a scholarly course on calling out crap

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

leisure time

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Patients' immediate access to test results puts radiologists in a bind

In diabetes hearing, Sanders takes on a new foe: food makers

SCOTUS to consider access to abortion pill mifepristone

After sickle

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

knowledge

explore

leisure time

focus